title: Glioma in 2014: unravelling tumour heterogeneity-implications for therapy.
abstract: Heterogeneity within and across tumours is increasingly recognized as a critical factor that limits therapeutic progress for many cancers. Key studies reported in 2014 describe previously unappreciated patterns of geographical and temporal heterogeneity for glioblastoma (the most-common primary CNS tumour in adults), with important implications for ongoing therapeutic studies evaluating molecular targeted therapies.
authors.affiliation: Center for Neuro-Oncology, Dana-Farber/Brigham &Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.affiliation: Center for Neuro-Oncology, Dana-Farber/Brigham &Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D018740:Genetic Heterogeneity; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab